ISPOR Europe 2025 brought together global HTA bodies, payers, industry leaders and patient organisations to discuss how evidence and access must evolve in a changing policy landscape.
Across three days, the conference focused on EU HTA implementation, patient-centred evidence, pragmatic RWE, global pricing pressures, and the future of HEOR science in an AI-enabled world.
The Remap Consulting team attended sessions across the full programme, including plenaries on patient engagement, JCA readiness, U.S. MFN policy, real-world data governance, and ISPOR’s newly announced Institute for Healthcare Transformation.
To support Market Access and HEOR teams navigating these shifts, we’ve brought together:
- All five ISPOR 2025 research posters presented by our team
- A concise, downloadable summary covering the most important insights and policy signals from the conference
ISPOR Europe 2025 Research Posters
Our team presented five research posters at ISPOR Europe 2025, each examining a major development in Market Access, EU HTA, pricing or evidence generation.
- What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to go Through the JCA?
Analysis of expected PICO structures for the first two products entering the EU Joint Clinical Assessment and the implications for manufacturers preparing JCA-aligned evidence packages. Access the research here
- How the EU JCA could interface with Regional Pricing Alliances (BeNeLuxA, Nordic Forum, Valletta Group) and EU-Level Procurement under the Critical Medicines Act?
An exploration of how regional alliances may incorporate JCA outputs, and how JCA timelines could act as a gateway to EU-level joint procurement. Access the research here
- Building the bridge to access: Leveraging RWE from early access schemes to reimbursement in gene and cell therapies
A review of how early-access RWE can support payer confidence in gene and cell therapies, including methodological considerations and evidence gaps. Access the research here
- Budget impact minimisation approaches used across Europe, Brazil, and Japan in the reimbursement of obesity medications
A cross-market assessment of how HTA bodies are addressing affordability pressures for obesity treatments, including BI thresholds, phased rollouts and risk-sharing models. Access the research here
- Revisiting rarity: Would yesterday’s NICE highly specialised technologies still qualify today?
An evaluation of past NICE HST decisions under the new 2025 routing criteria, assessing the future landscape for ultra-rare disease technologies. Access the research here
Download the Full ISPOR Europe 2025 Summary
Our full ISPOR Europe 2025 summary brings together the key themes, insights and policy updates that are most likely to influence Market Access and HEOR strategies in 2026 and beyond.
Inside, you’ll find analysis on:
- Collaboration, patient engagement and evidence transformation
- Pragmatic trials and decision-influential real-world evidence
- EU HTA implementation, JCA readiness and national PICO alignment
- Global pricing pressures, including U.S. MFN dynamics
- ISPOR’s future direction across science, policy and AI-enabled HEOR
Access the summary here